Kangmei Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio
Kangmei Pharmaceutical Co Ltd cash flow-to-debt ratio. Kangmei Pharmaceutical Co Ltd (600518) has a Cash Flow-to-Debt Ratio of 0.03x as of September 2025, meaning its operating cash flow of CN¥219.96 Million could theoretically repay 0% of its total liabilities (CN¥6.46 Billion) in one year. Check Kangmei Pharmaceutical Co Ltd cash earnings quality to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Kangmei Pharmaceutical Co Ltd (1999–2024)
Cash flow-to-debt ratio of Kangmei Pharmaceutical Co Ltd from 1999 to 2024. Historical debt coverage capacity for Kangmei Pharmaceutical Co Ltd across 26 annual periods. Check 600518 cash reinvestment to operating cash ratio to assess the company's total reinvestment commitment from operating cash flow.
Kangmei Pharmaceutical Co Ltd Cash Flow-to-Debt Ratio by Year (1999–2024)
Kangmei Pharmaceutical Co Ltd cash flow-to-debt ratio by year from 1999 to 2024. Year-by-year debt coverage analysis for Kangmei Pharmaceutical Co Ltd. For the full cash flow conversion analysis, see Kangmei Pharmaceutical Co Ltd (600518) cash conversion ratio.
| Year | CF-to-Debt Ratio | Operating CF (CNY) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -0.06x | CN¥-427.63 Million | CN¥6.59 Billion | ▼ -47.2% |
| 2023 | -0.04x | CN¥-317.52 Million | CN¥7.20 Billion | ▲ +51.9% |
| 2022 | -0.09x | CN¥-749.96 Million | CN¥8.18 Billion | ▼ -360.3% |
| 2021 | 0.04x | CN¥214.21 Million | CN¥6.09 Billion | ▲ +49.3% |
| 2020 | 0.02x | CN¥1.03 Billion | CN¥43.74 Billion | ▼ -64.0% |
| 2019 | 0.07x | CN¥2.88 Billion | CN¥43.94 Billion | ▲ +909.4% |
| 2018 | 0.01x | CN¥305.62 Million | CN¥47.03 Billion | ▲ +104.9% |
| 2017 | -0.13x | CN¥-4.84 Billion | CN¥36.78 Billion | ▼ -308.8% |
| 2016 | 0.06x | CN¥1.60 Billion | CN¥25.44 Billion | ▲ +138.6% |
| 2015 | 0.03x | CN¥508.86 Million | CN¥19.27 Billion | ▼ -74.0% |
| 2014 | 0.10x | CN¥1.13 Billion | CN¥11.16 Billion | ▼ -38.1% |
| 2013 | 0.16x | CN¥1.67 Billion | CN¥10.22 Billion | ▲ +19.8% |
| 2012 | 0.14x | CN¥1.01 Billion | CN¥7.38 Billion | ▲ +42.4% |
| 2011 | 0.10x | CN¥574.96 Million | CN¥5.99 Billion | ▼ -52.9% |
| 2010 | 0.20x | CN¥669.19 Million | CN¥3.28 Billion | ▲ +231.9% |
| 2009 | 0.06x | CN¥119.47 Million | CN¥1.95 Billion | ▲ +2532.9% |
| 2008 | 0.00x | CN¥3.02 Million | CN¥1.29 Billion | ▼ -98.7% |
| 2007 | 0.18x | CN¥162.55 Million | CN¥882.71 Million | ▲ +106.6% |
| 2006 | 0.09x | CN¥68.32 Million | CN¥766.30 Million | ▼ -85.5% |
| 2005 | 0.62x | CN¥133.13 Million | CN¥216.45 Million | ▲ +168.0% |
| 2004 | 0.23x | CN¥78.52 Million | CN¥342.09 Million | ▼ -22.8% |
| 2003 | 0.30x | CN¥78.02 Million | CN¥262.25 Million | ▲ +32.6% |
| 2002 | 0.22x | CN¥53.47 Million | CN¥238.35 Million | ▲ +118.1% |
| 2001 | 0.10x | CN¥15.69 Million | CN¥152.51 Million | ▲ +31.4% |
| 2000 | 0.08x | CN¥9.96 Million | CN¥127.27 Million | ▼ -70.0% |
| 1999 | 0.26x | CN¥30.25 Million | CN¥115.77 Million | — |